The polypill in the primary prevention of cardiovascular disease
|
|
- Barry Martin
- 5 years ago
- Views:
Transcription
1 doi: /j x REVIEW ARTICLE The polypill in the primary prevention of cardiovascular disease David S. Wald*, Nicholas J. Wald Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine, Queen Mary University, London EC1M 6BQ, UK Keywords heart attack, polypill, primary prevention, stroke Received 29 June 2009; revised 29 September 2009; accepted 23 October 2009 *Correspondence and reprints: ABSTRACT Coronary heart disease (CHD) and stroke are the most common causes of death worldwide. The polypill, a multi-component tablet or capsule designed to reduce several cardiovascular causal risk factors simultaneously, has the potential to reduce the incidence of heart attacks and stroke by about 80%, the precise reduction depending on the formulation of the polypill and adherence to preventive treatment. The full public health impact can only be realized if the polypill is used to prevent first cardiovascular disease events, because most heart attacks and strokes are first events. A simple and effective method of selecting who should be offered the polypill is needed. Even though serum cholesterol and blood pressure are important causes of CHD and stroke and lowering them has a large preventive effect (a 1.8 mmol/l reduction in LDL cholesterol reduces the incidence of CHD events by about 60% and a 10 mmhg reduction in diastolic blood pressure also reduces the incidence of stroke by about 60%), they are poor screening tests. They add little to age in discriminating between individuals who will and will not have a CHD event or stroke. Including them in a risk assessment algorithm needlessly complicates the screening process and tends to medicalize the preventive strategy. Age alone is effective and a simpler means of selecting people for preventive treatment using the polypill. In 2003 Wald and Law, with colleagues, published a set of three papers [1 3], based on a patent application filed in 2000 [4]. They proposed a combination fixed dose medical formulation designed to modify several causal cardiovascular risk factors simultaneously and called this the polypill. They proposed a new preventive approach (the polypill approach) in which preventive treatment would be used by everyone above a specified age (e.g. 55) regardless of their starting risk factor levels and showed that a six component polypill could, with full adherence to preventive treatment, reduce a person s risk of coronary heart disease (CHD) and stroke by about 80%. The principle cardiovascular risk factors lowered by a polypill are LDL cholesterol (e.g. with a statin) and blood pressure (e.g. with ACE-inhibitors, angiotensin receptor blockers, thiazides, beta blockers, or calcium channel blockers). Reducing platelet aggregation (e.g. with aspirin) and serum homocysteine (e.g. with folic acid) are options. All the components have been shown to reduce the risk of CHD and stroke in randomized trials, except folic acid, which is inferred from epidemiological studies. Since 2003 several groups have developed polypills, demonstrating the feasibility of incorporating multiple drug components in a single tablet or capsule [5,6]. Efficacy in preventing heart attacks and strokes is likely to be similar for the different proposed polypills (about an 80% preventive effect on CHD events and 70% on stroke for a polypill with aspirin, a statin and two or more blood pressure components). The variations in formulation and dose will, however, affect tolerability and the incidence of serious adverse effects (such as gastric and intracranial bleeding with aspirin), which will influence the choice of polypill [7,8]. A polypill without aspirin may be preferred for primary prevention because the absolute risk of haemorrhage may be too great in relation to the absolute 29
2 30 D.S. Wald & N.J. Wald risk reduction [9], but it confers a net benefit in a polypill for people who have had an ischaemic event. The inclusion of folic acid in the polypill is an open question given the uncertainty over the benefits of homocysteine reduction. Did not die of CHD Died of CHD DR = 13% THE POLYPILL APPROACH FPR = 5% The proposed polypill approach recognizes the fact that, within the range of usual risk factor levels, there are no risk factor thresholds above which treatment is needed and below which treatment is not needed. Cohort studies show that within the usual physiological range of blood pressure, cholesterol and serum homocysteine, there are no thresholds below which a further decrease in the risk factor is not associated with a further decrease in risk [10 13]. The polypill approach also recognizes that there is benefit in reducing causal risk factor levels in people at high risk of cardiovascular disease, whatever the reason for their high risk and regardless of the level of the risk factor. In other words, treatment should not be limited to people with hypertension or hypercholesterolaemia. The proposed approach differs from the standard method of selecting individuals for preventive treatment by not using serum cholesterol or blood pressure measurements to determine who receives preventive treatment. This is perhaps surprising, as reducing these risk factors is so important in preventing heart disease and stroke. The reason they are not very effective in determining who should receive preventive treatment, i.e. as screening tests [14,15], is that nearly all adults have high risk factors, so the risk factors, whilst responsible for most cases of the diseases they cause, do little to distinguish between those who will and those who will not become affected by these diseases. SINGLE CARDIOVASCULAR RISK FACTORS AS SCREENING TESTS Figure 1 shows the relative distribution of diastolic blood pressure in people who did (right curve) and did not (left curve) die of CHD in a large cohort study [16]. There is substantial overlap between the two distributions. If a blood pressure cut-off were chosen that classified 5% of individuals who did not later die of CHD over a given period, as being high risk (a commonly used falsepositive rate in screening), then only 13% of those who did die of CHD in the same period would be identified. The screening performance is poor; a detection rate of 13% for a 5% false positive rate Diastolic blood pressure (mmhg) Figure 1 The distribution of diastolic blood pressure levels in people who did and did not die of coronary heart disease (CHD) in the BUPA cohort study [16]. The detection rate (DR, sensitivity) is shown for a 5% false positive rate (FPR). In clinical practice, a blood pressure cut-off is usually specified (e.g. a diastolic of 90 mmhg), above which individuals are regarded as high risk (hypertensive) and offered treatment, and below which they are not. However, the substantial overlap between the two distributions means that it is not possible to select a blood pressure level that identifies most people who develop CHD without including a large proportion of people who do not. If a blood pressure level of 90 mmhg were selected as the cut-off, as in Figure 2, 52% of all people who develop CHD would be classified as high risk (and offered treatment), but so too would 38% of those who do not; the discrimination is little better than selecting people for treatment at random. Moreover, 48% of people who will develop CHD (in the dark shaded area), would be classified as low risk and so be excluded FNR = 48% Did not die of CHD Died of CHD DR = 52% FPR = 38% Diastolic blood pressure (mmhg) Figure 2 The distribution of diastolic blood pressure levels in people who did and did not die of coronary heart disease (CHD) in the BUPA cohort study [16]. The dark shaded area shows the proportion of people with CHD who would be misclassified as low risk using a diastolic blood pressure cut-off of 90 mmhg. (DR = detection rate; FPR = false-positive rate; FNR = false negative rate).
3 The polypill in the primary prevention of cardiovascular disease 31 from useful treatment. Screening performance is similar for other cardiovascular risk factors, like serum cholesterol, homocysteine, body mass index or HbA1c [17 20]. MULTIPLE CARDIOVASCULAR RISK FACTORS AS SCREENING TESTS It may appear intuitive that combining several risk factors (e.g. based on a Framingham, SCORE or QRISK2 algorithm) [21 23] to derive an individual s risk of a cardiovascular disease event may overcome the poor screening performance of individual risk factors. This may have prompted the UK Government, in April 2009, to introduce population screening for cardiovascular disease based on multiple risk factor measurement in people aged without prior cardiovascular disease or diabetes [24]. The programme, initially called Vascular Checks and now termed NHS Health Checks, involves the calculation of a person s risk of developing a CHD event or stroke, based on age, weight, smoking, blood pressure and blood cholesterol using either the Framingham or QRISK2 algorithm (QRISK2 adds information on family history, ethnicity and social deprivation). Whichever risk assessment is used, the risk estimate itself is the screening test. If a person s risk of cardiovascular disease is judged to be high (>20% over 10 years), he or she is screen-positive and life-style advice (mainly to reduce weight and increase exercise) is given and interventions such as cholesterol lowering drugs may be offered. At moderate risk (10 20% over 10 years), lifestyle advice alone is given. If the risk estimation is low (<10% over 10 years), individuals are reassured and encouraged to maintain healthy life-style behaviour. The problem with this approach is that weakly predictive risk factors combining risk factors in this way has a small effect on improving screening performance compared to using one. Table I (based on men who did and did not die in the UK BUPA cohort study) [15] shows that adding a second or third risk factor adds little to the ability to separate individuals who will develop CHD from those who will not. For example, either systolic blood pressure (SBP) or apob detects 17% of individuals who die of CHD at a 5% false-positive rate. If both risk factors are used together and a person is designated screen-positive if either or both are positive, the detection rate is slightly less than twice as great (31%, calculated as 1 [1 0.17] 2 ), but the falsepositive rate is also about twice as great (9.75%). The key question is whether this detection rate of 31% is substantially higher than that from using either blood pressure or apob alone, at a 10% false-positive rate. It is Table I Illustration of the effect of combining risk factors on screening performance using estimates of the detection rate for various combinations of cardiovascular risk factors at 5% and 10% false-positive rates (adapted from Wald et al. [15]). Screening variable Detection rate (%) 5% false-positive rate Systolic blood pressure (SBP) alone 17 ApoB alone 17 SBP and apob 22 SBP, apob, apoai, apo(a) 24 SBP, apob, apoai, apo(a), smoking 27 SBP, apob, apoai, apo(a), smoking, family history 28 10% false-positive rate SBP alone 26 apob alone 28 SBP and apob 34 SBP, apob, apoai, apo(a) 36 SBP, apob, apoai, apo(a), smoking 40 SBP, apob, apoai, apo(a), smoking, family history 41 apob (protein component of LDL cholesterol). apoai (protein component of HDL cholesterol). apo(a) (protein component of lipoprotein a). not; the detection rate is 26% for blood pressure alone and 28% for apob alone (Table I). The gain in detection at the same false-positive rate from using both together over the more discriminatory of the two measurements (apob) alone is only about 4 percentage points. Adding the second risk factor adds relatively little to the first and adding a third or fourth adds even less. ApoB is the main surface protein on LDL particles and has been shown to be more strongly associated with CHD than its lipid fraction, LDL cholesterol [25], so measurement of LDL (or total) cholesterol instead of ApoB would be less, rather than more informative about an individual s future risk. Assessment of subclinical atherosclerosis, for example using carotid ultrasound to measure intima-media thickness, has been proposed as an alternative screening method, but the discrimination is only marginally better (19% detection rate for a 5% falsepositive rate) [26]. Figure 3 shows that about 20 risk factors, comparable with serum cholesterol or blood pressure as predictors of cardiovascular disease events, would be needed to detect 80% of cases at a 5% falsepositive rate [27]. Even if there were this many risk factors, their use would probably be complex and costly. Although multiple risk factor screening is widely adopted it is a questionable policy. Another issue is that the 20% risk cut-off of having a heart attack or stroke over 10 years that is used to trigger preventive treatment is too high. Whilst an
4 32 D.S. Wald & N.J. Wald Detection rate (%) Number of risk factors 20 Figure 3 Detection rate (sensitivity) for a 5% false positive rate according to the number of independent risk factors (each with a detection rate of 15% for a 5% false positive rate) used in combination (adapted from Wald et al. [27]). individual, at this risk cut-off, has a 1 in 50 chance of a heart attack or stroke each year and would be offered preventive treatment, someone below the risk cut-off, say with a 1 in 100 risk (10% over 10 years), would not be offered the treatment. If someone knew he or she had a 1 in 100 chance of a heart attack or stroke over the next 12 months, that person is unlikely to be satisfied with reassurance or dietary advice when simple and effective treatment could reduce this by about 75%. Limiting treatment to a minority of the population may be defendable if the preventive treatments were toxic or expensive, but they are not. Statins and blood pressure lowering drugs are remarkably safe and generic, so cost little. People willingly pay much more for other precautionary measures, like home insurance, when the risk of serious damage is far lower and less devastating than having a heart attack or stroke. AGE AS A SCREENING ENQUIRY As about 95% of all heart attack and stroke deaths in England and Wales occur in people aged 55 and over [28], age 55 has been proposed as the entry point for preventive treatment [1]. Figure 4 (based on England and Wales registry data [16]) shows that at age 55, the risk of a first coronary heart disease event or stroke over Figure 4 Risk of a first coronary heart disease event or stroke according to age based on published one-year risks, derived from registry data in England and Wales [16] (allowing for the increase in risk over the 10 year period). the next 10 years is about 4% (or about 1 in 250/year) and doubles every 7 years. Offering preventive treatment to all over a specified age is simple and equitable. It recognizes that an effective preventive strategy needs to be conceptually inclusive, given that heart attacks and strokes are common, killing one in three people [28]. The proposed approach is similar to that adopted in most vaccination programmes, where there is no attempt at selecting high and low risk groups who should or should not be offered vaccination. An age-based approach has the benefit of not medicalizing the population; individuals are not selected as having hypertension or hypercholesterolaemia and thus do not become patients to receive preventive treatment. Multiple risk factor screening does medicalize people and serves only to delay the start of treatment in some by a few years because everyone becomes high risk as they become a few years older. RECENT DEVELOPMENTS AND FUTURE CHALLENGES Several trials assessing the effect of polypills on risk factor reduction are underway and one has been reported [5]. The Indian Polycap Study (TIPS) trial on about 2000 people showed that a Polypill (Polycap) can be made and
5 The polypill in the primary prevention of cardiovascular disease 33 can be used safely by healthy people. The mean age was 54 years, mean blood pressure was 135/86 mmhg and mean LDL cholesterol was 3.0 mmol/l. The serum cholesterol and blood pressure reductions in TIPS were thought to be smaller than the estimates from metaanalyses of trials of the individual components [5]. However, there was no inconsistency with respect to LDL reduction; (a reduction of 0.7 mmol/l rather than 1.8 mmol/l). The lower pre-treatment cholesterol in the TIPS trial (3.0 mmol/l compared with 4.8 mmol/l in the meta-analysis of trials) taken together with the lower dose of simvastatin used in TIPS (20 mg, not 40 mg) and non-adherence to prescribed therapy explains this difference. The blood pressure reductions observed in TIPS (7.4/5.6 mmhg) were smaller than expected allowing for pre-treatment blood pressure and non-adherence [29,30]. This is unexplained and the TIPS authors acknowledge this. Trials assessing the effect of Polypills on reducing first heart attacks and strokes are planned or underway [30]. The main question in these trials is not on efficacy and safety but on adherence and tolerability. Intolerance to one component (for example, an ACE-inhibitor, which causes cough in about 1 in 10 people) [31] may result in the Polypill being stopped. Encouraging continuation with preventive treatment, even in the absence of sideeffects, is a challenge, and strategies to incentivize adherence need to be developed and tested. Polypills are new medicinal products but their components are not new. The regulatory standards that apply to the approval of new chemical entities should not automatically apply to polypills [32]. Bioequivalence studies (studies that show that taking a polypill is equivalent or nearly equivalent in terms of absorption and blood levels as taking the individual components) should be sufficient for a Regulatory Authority to approve the drug for use with indications of use that apply to use of the components in medical practice. If the components are effective in cardiovascular disease prevention, the indications for use of a polypill containing such components should extend to this, even if there is already no such licensed use (usually because no company has applied for one). So, for example, it should be possible to license a polypill with a statin and three blood pressure-lowering drugs for the primary prevention of cardiovascular disease, not just the treatment of hypercholesterolaemia or hypertension. It is in the public interest for regulators and scientists to be flexible and to work together to simplify the development, delivery and approval of polypills, so preventive treatment is accessible and affordable to all who stand to benefit. COST-EFFECTIVENESS OF THE POLYPILL APPROACH A polypill, based on generic drugs that lower cholesterol and blood pressure, might cost about 400 per person per year. If all people aged 55 and older took such treatment for 25 years (average life expectancy from age 55), the total cost per person would be about Approximately, one in three people who take treatment would benefit and he or she would gain about 11 years of life without a heart attack or stroke [1], that is about 2500 for each year of life gained without a heart attack or stroke [( )/11]. There would be almost no costs attached to screening, allowing general practitioners and other health care professionals to focus attention on other health matters instead of engaging in relatively ineffective selection and administrative activities. This is a simple calculation to indicate what the approximate cost could be. Adherence to preventive therapy is uncertain and hence the overall benefit may be less, but even if the polypill prevented only half the estimated proportion of events, it would still be cost-effective. With direct access to the public, for example, through pharmacist prescribing, the cost could, in part, be moved from national health care budgets to the individual. Employers, who wish to retain healthy employees over age 55 at work would also have an incentive to subsidize the preventive treatment costs to their staff. In a few years, polypills are likely to be available in many countries. They are already available in India. While formulation, tolerability and cost are important, the extent to which polypills will achieve their full preventive potential will depend largely on specifying a policy that ensures that all who may benefit are able to obtain them. There is general agreement that people who have already had a heart attack or stroke will benefit. However, the current neglect in preventing first events is a mistake; every person who has had a second or subsequent heart attack or stroke has had a first event and the priority should be to prevent the first event. If a first event is prevented, there is no second event to prevent. KEY POINTS The polypill approach (offering it to people above a certain age, say 55) without medical examination or risk factor measurement is simple and could save millions of lives a year worldwide. Preventive treatment should reduce several causal risk factors, even if they are not raised.
6 34 D.S. Wald & N.J. Wald Causal risk factors such as serum cholesterol and blood pressure are important aetiologically, but are poor screening tests, both individually and in combination with other risk factors. Current cardiovascular disease prevention strategies based multiple risk factor measurement should be reviewed. Primary prevention of cardiovascular disease is the priority. FUNDING SOURCES None. DECLARATION OF INTEREST Nicholas J Wald holds patents (EU and GB ) for a combination pill for the prevention of cardiovascular disease and, together with David Wald, has interests in its development. ACKNOWLEDGEMENT We are grateful to Mark Simmonds for his comments on the manuscript and for preparing Figure 4. REFERENCES 1 Wald N.J., Law M.R. A strategy to reduce cardiovascular disease by more than 80%. BMJ (2003) Law M.R., Wald N.J., Morris J.K., Jordan R.E. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ (2003) Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ (2003) European patent specification: formulation for the prevention of cardiovascular disease. EP B1. Proprietors Wald N.J., Law M.R.; priority The Indian Polycap Study (TIPS). Effects of a polypill (Polycap) on risk factors in middle aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet (2009) Phase 2 study of heart polypill safety and efficacy in primary prevention of cardiovascuolar disease. ct2/show/nct DOI 15/6/ Derry S., Loke Y.K. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ (2000) McQuaid K.R., Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am. J. Med. (2006) Antithromobotic Trialists (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) MacMahon S., Peto R., Cutler J. et al. Blood pressure, stroke and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet (1990) Neaton J.D., Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Arch. Intern. Med. (1992) Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet (2002) Wald D.S., Law M.R., Morris J. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ (2002) Wald N.J., Hackshaw A.K., Frost C.D. When can a risk factor be used as a worthwhile screening test? BMJ (1999) Wald N.J., Law M., Watt H. et al. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet (1994) Law M., Wald N.J., Morris J. Lowering blood pressure to prevent myocardial infarction and strokes: a new preventive strategy. Health Technol. Assess. (2003) 7 No Law M.R., Wald N.J., Wu T., Hackshaw A., Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ (1994) Law M., Morris J. The dose response relationship between serum homocysteine and cardiovascular disease:implications for screening and treatment. Eur J Cardiovasc Prev Rehabil (2004) Prospective Studies Collaboration. Body-mass index and causespecific mortality in adults; collaborative analyses of 57 propsective studies. Lancet (2009) Khaw K.T., Wareham N., Luben R. et al. Glycated haemoglobin, diabetes and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIV-Norfolk). BMJ (2001) D Agostino R.B., Vasan R.S., Pencina M.J. et al. General cardiovascular risk profile for use in primary care. the Framingham heart study. Circulation (2008) De Backer G., Ambrosioni E., Borch-Johnsen K. et al. Executive summary. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts. Eur. Heart J. (2003) Hippisley-Cox J., Coupland C., Vinogradova Y. et al. Predicting cardiovascular risk in England and Wales: prospective deri-
7 The polypill in the primary prevention of cardiovascular disease 35 vation and validation of QRISK2. A new cardiovascular disease risk score for the UK. BMJ (2008) 336(7659) Department of Health. Putting prevention first. NHS Health Check: Vascular Risk Assessment and Management. PublicationsPolicyAndGuidance/DH_ Parish S., Peto R., Palmer A. et al. The joint effects of apolipoprotein B, apolipoprotein A 1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acuts myocardial infarction and 9805 controls. Eur. Heart J. (2009) 30) Wald D.S., Bestwick J.P. Carotid ultrasound screening for coronary heart disease: results based on a meta-analysis of 18 studies and 44,861 subjects. J. Med. Screen. (2009) Wald N.J., Morris J.K., Rish S. The efficacy of combining several risk factors as a screening test. J. Med. Screen. (2005) Office for National Statistics. Mortality Statistics Cause Wald N., Law M. The Indian Polycap Study (TIPS). Lancet (2009) Yusuf S., Pais P., Xavier D. The Indian Polycap Study (TIPS): Authors reply. Lancet (2009) The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. (2000) Sleight P., Pouleur H., Zannad F. Benefits, challenges, and registerability of the polypill. Eur. Heart J. (2006)
The future of coronary heart disease prevention
The future of coronary heart disease prevention David S Wald MA MD MRCP, Consultant Cardiologist and Senior Lecturer, Wolfson Institute of Preventive Medicine, and London Chest Hospital Barts and The London,
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationPapers. A strategy to reduce cardiovascular disease by more than 80% Abstract. Methods. Introduction. N J Wald, M R Law
A strategy to reduce cardiovascular disease by more than 80% N J Wald, M R Law Abstract Objectives To determine the combination of drugs and vitamins, and their doses, for use in a single daily pill to
More informationGuidelines on cardiovascular risk assessment and management
European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine
More informationReducing CVD globally through combination approaches to prevention: the polypill. Salim Yusuf
Reducing CVD globally through combination approaches to prevention: the polypill. Salim Yusuf Disclosure None Polypill & CVD Prevention 1. Why do we need a polypill? 2. What components in the polypill?
More informationAppendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.
Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular
More informationCosting report: Lipid modification Implementing the NICE guideline on lipid modification (CG181)
Putting NICE guidance into practice Costing report: Lipid modification Implementing the NICE guideline on lipid modification (CG181) Published: July 2014 This costing report accompanies Lipid modification:
More informationThe Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4)
The Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4) Denis Xavier MD, MSc Professor and Head, Pharmacology, St. John's Medical College Coordinator, Division
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:
More informationDiscontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database
open access Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database Yana Vinogradova, 1 Carol Coupland, 1 Peter Brindle, 2,3 Julia Hippisley-Cox
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More informationThe All Wales Medicine Strategy Group (AWMSG) is asked to support implementation of the following prescribing indicators.
ENCLOSURE 5 APPENDIX 1 Paper presented to AWMSG in June 2006 AWPAG considered comments recorded in AWMSG minutes in July 2006 Paper subsequently updated and brought back to AWMSG for endorsement This paper
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Peripheral arterial disease Potential output:
More informationIs there a mechanism of interaction between hypertension and dyslipidaemia?
Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational
More informationPlacebo-Controlled Statin Trials
PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of
More informationVascular Diseases. Overview: Selected Slides
Vascular Diseases Overview: Selected Slides Total deaths and change in vascular death rates
More informationrosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd.
rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationRepeat ischaemic heart disease audit of primary care patients ( ): Comparisons by age, sex and ethnic group
Repeat ischaemic heart disease audit of primary care patients (2002-2003): Comparisons by age, sex and ethnic group Baseline-repeat ischaemic heart disease audit of primary care patients: a comparison
More informationPrimary Prevention of Stroke
Primary Prevention of Stroke Dr Chris Ellis Cardiologist Green Lane CVS Service, Auckland City Hospital & Auckland Heart Group, Mercy Hospital, Auckland 67 Pages Long, 735 References 29 Sub-Headings for
More informationLow-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society
More informationNational Medicines Information Centre
National Medicines Information Centre VOLUME 8 NUMBER 6 2002 ST. JAMES S HOSPITAL DUBLIN 8 TEL 01-4730589 or 1850-727-727 FAX 01-4730596 E-Mail: nmic@stjames.ie If you would like to receive NMIC publications
More informationStatins ARE Enough For The Prevention of CVD! Professor Kausik Ray Imperial College London, UK
1 Disclosures Advisory boards PCSK9- Sanofi/ Regeneron, Amgen, Pfizer, Roche, MSD NLI/ SC member for Odyssey- (Sanofi/ Regeneron), Roche Investigator initiated research grant support (Sanofi/Regeneron/
More informationPrimary care. Coronary heart disease prevention: insights from modelling incremental cost effectiveness. Abstract. Methods. Introduction.
Coronary heart disease prevention: insights from modelling incremental cost effectiveness Tom Marshall Abstract Objective To determine which treatments for preventing coronary heart disease should be offered
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationASPIRIN AND VASCULAR DISEASE
ASPIRIN AND VASCULAR DISEASE SUMMARY Aspirin is an effective antiplatelet agent for patients with cardiovascular and cerebrovascular disease. Incidence of adverse effects and drug interactions increases
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationLOCAL PERIPROSTATIC ANESTHESIA BETWEEN OPTION AND NECESSITY IN TRANSRECTAL ULTRASOUND - GUIDED PROSTATE BIOPSY
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2013 vol. 117, no. 1 SURGERY ORIGINAL PAPERS LOCAL PERIPROSTATIC ANESTHESIA BETWEEN OPTION AND NECESSITY IN TRANSRECTAL ULTRASOUND - GUIDED PROSTATE BIOPSY B. Novac¹,
More informationRESEARCH. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study
Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study Julia Hippisley-Cox, professor of clinical epidemiology and general practice,
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationModule 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More information33 Polypill Co-Prescription for at
33 Polypill Co-Prescription for at the Risk Asian Indian in Chronic Non-Communicable Diseases Abstract: Wald and Law s original 2003 BMJ paper on the Polypill, introduced the idea although it used data
More informationNew approaches to the implementation of cardiovascular disease prevention Jørstad, H.T.
UvA-DARE (Digital Academic Repository) New approaches to the implementation of cardiovascular disease prevention Jørstad, H.T. Link to publication Citation for published version (APA): Jørstad, H. T. (2016).
More informationTHE ESC/EAS LIPID GUIDELINES IN THE ELDERLY
THE ESC/EAS LIPID GUIDELINES IN THE ELDERLY Alberico L. Catapano alberico.catapano@unimi.it Alberico L. Catapano Potential Conflict Of Interest Prof. Catapano has received honoraria, lecture fees, or research
More informationModelling Reduction of Coronary Heart Disease Risk among people with Diabetes
Modelling Reduction of Coronary Heart Disease Risk among people with Diabetes Katherine Baldock Catherine Chittleborough Patrick Phillips Anne Taylor August 2007 Acknowledgements This project was made
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationThe polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population
Open Access To cite: van Gils PF, Over EAB, Hamberg-van Reenen HH, et al. The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population. BMJ Open 2011;1:e000363.
More information2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.
2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature
More informationwell-targeted primary prevention of cardiovascular disease: an underused high-value intervention?
well-targeted primary prevention of cardiovascular disease: an underused high-value intervention? Rod Jackson University of Auckland, New Zealand October 2015 Lancet 1999; 353: 1547-57 Findings: Contribution
More informationDr. Sandeep Bhattacharya, Chief Innovation & Strategy Officer, Merck & Co., Inc. / MSD Asia Pacific
Dr. Sandeep Bhattacharya, Chief Innovation & Strategy Officer, Merck & Co., Inc. / MSD Asia Pacific Disclaimer: The opinions expressed in this presentation are the personal opinions of the speaker & do
More informationTrends and Variations in General Medical Services Indicators for Coronary Heart Disease: Analysis of QRESEARCH Data
Trends and Variations in General Medical Services Indicators for Coronary Heart Disease: Analysis of QRESEARCH Data Authors: Professor Julia Hippisley-Cox Professor Mike Pringle Professor of Clinical Epidemiology
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationStroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital
Stroke secondary prevention Gill Cluckie Stroke Nurse Consultant St. George s Hospital Stroke recurrence The risk of recurrent stroke is greatest after first stroke 2 3% of survivors of a first stroke
More informationComments from AstraZeneca UK Ltd
13 June 2007 NICE HTA: Ezetimibe for the treatment of primary (heterozygous familial and nonfamilial) hypercholesterolemia Appraisal Consultation Document (ACD) Many thanks for providing the ACD for the
More informationRandomized Polypill Crossover Trial in People Aged 50 and Over
in People Aged 50 and Over David S. Wald, Joan K. Morris, Nicholas J. Wald* Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London,
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationHowever, if instead, CHD risk is plotted on a doubling scale (as in slide 2) then there is a
Slides 1 and 2: These two illustrative slides (based on notionaldata) were used in my presentation to Dr Godlee at our meeting on 2 December 2013 to show that, if the risk of coronary disease (CHD) is
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction 1.1
More informationNIH Public Access Author Manuscript Am Heart J. Author manuscript; available in PMC 2012 April 1.
NIH Public Access Author Manuscript Published in final edited form as: Am Heart J. 2011 April ; 161(4): 719 725. doi:10.1016/j.ahj.2010.12.019. Projected impact of polypill use among US adults: medication
More informationDiabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care
open access Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care Julia Hippisley-Cox, Carol Coupland Division of Primary Care, University
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationUsing the New Hypertension Guidelines
Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in
More informationFamily history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study
1 Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands 2 Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands 3 Department of Public Health and
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationCost-effectiveness of evolocumab (Repatha ) for hypercholesterolemia
Cost-effectiveness of evolocumab (Repatha ) for hypercholesterolemia The NCPE has issued a recommendation regarding the cost-effectiveness of evolocumab (Repatha ). Following NCPE assessment of the applicant
More informationCE: lavanya ED: soumen: Op: vp HJR: LWW_HJR_200433
CE: lavanya ED: soumen: Op: vp HJR: LWW_HJR_200433 Original Scientific Paper Heartwatch: a secondary prevention programme in primary care in Ireland Kathleen Bennett a, Siobhan Jennings b, Claire Collins
More informationClinical Recommendations: Patients with Periodontitis
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;
More informationBlood Pressure Lowering Efficacy of Perindopril/ Indapamide Fixed Dose Combination in Uncontrolled Hypertension
525 Blood Pressure Lowering Efficacy of Perindopril/ Indapamide Fixed Dose Combination in Uncontrolled Hypertension PHIMDA Kriangsak 1* and CHOTNOPARATPAT Paiboon 2 1 Diabetes and Hypertension Clinic,
More informationPreventing Cardiovascular Disease Stroke Primary Prevention Guidelines. John Potter Professor Ageing & Stroke Medicine University of East Anglia
Preventing Cardiovascular Disease Stroke Primary Prevention Guidelines John Potter Professor Ageing & Stroke Medicine University of East Anglia Preventing Cardiovascular Disease Stroke Primary Prevention
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationCarotid Ultrasound Scans for Assessing Cardiovascular Risk
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/carotid-ultrasound-scans-for-assessing-cardiovascularrisk/4004/
More informationPrimary care. Abstract. Introduction. Tom Marshall, Andrew Rouse
Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study Tom Marshall, Andrew Rouse Abstract Objective
More information5.2 Key priorities for implementation
5.2 Key priorities for implementation From the full set of recommendations, the GDG selected ten key priorities for implementation. The criteria used for selecting these recommendations are listed in detail
More informationData Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial
Data Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial 1 Background This Data Analysis Plan describes the strategy, rationale and statistical methods
More information03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE
CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE Elizabeth L. Detschelt, M.D. Allegheny Health Network Vascular and Endovascular Symposium April 2, 2016 DISCLOSURES I have no
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationSIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence
SIGN 149 Risk estimation and the prevention of cardiovascular disease Quick Reference Guide July 2017 Evidence ESTIMATING CARDIOVASCULAR RISK R Individuals with the following risk factors should be considered
More informationClinical Care Performance. Financial Year 2012 to 2018
Clinical Care Performance Financial Year 2012 to 2018 SHP Clinical Care Performance Diabetes Mellitus Hyperlipidemia Hypertension Diabetes Mellitus Find out how our patients are doing for: HbA1C HbA1c
More informationHIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES
HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES A study published in the British Medical Journal shows that not only is high LDL cholesterol not a risk factor for all-caused
More informationEffects of Statins on Endothelial Function in Patients with Coronary Artery Disease
Effects of Statins on Endothelial Function in Patients with Coronary Artery Disease Iana I. Simova, MD; Stefan V. Denchev, PhD; Simeon I. Dimitrov, PhD Clinic of Cardiology, University Hospital Alexandrovska,
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationTime Series Analysis for selected clinical indicators from the Quality and Outcomes Framework
Time Series Analysis for selected clinical indicators from the Quality and Outcomes Framework 21-26 Title Document Type Time Series Analysis for selected clinical indicators from the Quality and Outcomes
More informationReducing low-density lipoprotein cholesterol treating to target and meeting new European goals
European Heart Journal Supplements (2004) 6 (Supplement A), A12 A18 Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals University of Sydney, Sydney, NSW, Australia
More informationESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study
ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study Statistical modelling details We used Cox proportional-hazards
More informationComplications of Diabetes mellitus. Dr Bill Young 16 March 2015
Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationOptimal Design of Multiple Medication Guidelines for Type 2 Diabetes Patients
Optimal Design of Multiple Medication Guidelines for Type 2 Diabetes Patients Jennifer E. Mason PhD Student Edward P. Fitts Department of Industrial and Systems Engineering NC State University, Raleigh,
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationQuantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and metaanalysis M R Law, N J Wald, A R Rudnicka Abstract Objectives To determine
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationType of intervention Primary prevention; secondary prevention. Economic study type Cost-effectiveness analysis and cost utility analysis.
A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients Milne R J, Hoorn S V, Jackson R T Record
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationKey causes of preventable deaths in New Zealand In a population of 10,000 New Zealanders, every year there will be about:
Preventive care - Chronic Disease Management in primary care: a population perspective Rod Jackson University of Auckland New Zealand (22/11/8) Key causes of preventable deaths in New Zealand In a population
More informationSummary of recommendations
Summary of recommendations Measuring blood pressure (BP) Use the recommended technique at every BP reading to ensure accurate measurements and avoid common errs. Pay particular attention to the following:
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationOverview. NOT A REPETION OF LOCAL GUIDELINE Dr Diviash Thakrar
Overview 1. Why hypertension is important? 2. What are basic principles in treatment? 3. Different ways of measuring 4. Hypercholesterolemia NOT A REPETION OF LOCAL GUIDELINE CVD risk factors? Non modifiable
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
1980 to 2000: Death rate fell from: 542.9 to 266.8 per 100K men 263.3 to 134.4 per 100K women 341,745 fewer deaths from CHD in 2000 Ford ES, NEJM, 2007 47% from CHD treatments, 44% from risk factor modification
More informationYounger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.
Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.
More informationWeintraub, W et al NEJM March Khot, UN et al, JAMA 2003
Global risk hscrp Should not be included in a Global Cardiovascular Risk Assessment. Jodi Tinkel, MD Assistant Professor Director of Cardiac Rehabilitation Associate Program Director, Cardiovascular Medicine
More informationBeyond LDL-Cholesterol
Biomarkers for Risk Stratification Beyond LDL-Cholesterol Athanasios J.Manolis Director Cardioilogy Dep, Asklepeion Hospital, Athens, Greece Adj. Professor of Medicine, Emory University Atlanta, USA Adj.
More informationRESEARCH. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database
Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database Julia Hippisley-Cox, professor of clinical epidemiology and general practice,
More informationMRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebocontrolled
Articles MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebocontrolled trial Heart Protection Study Collaborative Group* Summary Background
More informationIdentification and management of familial hypercholesterolaemia (FH) - An overview
Identification and management of familial hypercholesterolaemia (FH) - An overview National Collaborating Centre for Primary Care and Royal College of General Practitioners NICE Guideline CG 71 (August
More information